Continuing a recent trend, strong sales growth from its Definity and TechneLite products propelled Lantheus Medical Imaging parent Lantheus Holdings to an increase in revenue for its first quarter.
For the period (end-March 31), Lantheus had worldwide revenues of $86.5 million, up 4.7% from $82.6 million in the first quarter of 2018. Following up on strong performances in previous quarters, the Definity ultrasound contrast agent and TechneLite radiopharmaceutical both produced double-digit sales gains in the period, according to the firm. Lantheus had first-quarter net income of $9.9 million, compared with net income of $8.2 million in the same period last year.
Looking ahead, Lantheus said it expects second-quarter revenue to range between $86 million and $90 million, representing a growth rate range of 0.5% to 5.2%. It also anticipates that adjusted diluted earnings per share will range between $0.23 and $0.28 in the second quarter. In addition, the company affirmed its full-year revenue and earnings guidance.
